FMR LLC 13D and 13G filings for Allogene Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-07 10:01 am Sale |
2025-02-28 | 13G | Allogene Therapeutics, Inc. ALLO |
FMR LLC | 10,225,851 4.900% |
-13,546,144 (-56.98%) |
Filing |
| 2025-02-12 09:16 am Sale |
2024-12-31 | 13G | Allogene Therapeutics, Inc. ALLO |
FMR LLC | 23,771,995 11.300% |
-1,469,504 (-5.82%) |
Filing |
| 2024-02-09 08:35 am Purchase |
2024-02-08 | 13G | Allogene Therapeutics, Inc. ALLO |
FMR LLC | 25,241,499 14.999% |
323,544 (+1.30%) |
Filing |
| 2023-07-10 10:20 am Purchase |
2023-07-07 | 13G | Allogene Therapeutics, Inc. ALLO |
FMR LLC | 24,917,955 17.085% |
24,917,955 (New Position) |
Filing |